Addex Therapeutics Ltd
ADXN · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -18.3% | – | -100% | – |
| Gross Profit | $0 | -$0 | $0 | $0 |
| % Margin | 100% | -544.5% | – | 100% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -5,297.5% | -5,377.2% | – | -77,224.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -5,306.3% | -5,061.6% | – | -79,956% |
| EPS Diluted | -1.2 | -2.4 | -1.8 | -1.48 |
| % Growth | 50% | -33.3% | -21.6% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |